The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Open accessAbstract
BACKGROUND: Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer. METHODS: Patients in Japan with stage II or III gastric cancer who underwent gastrectomy with extended (D2) lymph-node dissection were randomly assigned to undergo surgery followed by adjuvant therapy with S-1 or to undergo surgery only. In the S-1 group, administration of S-1 was started within 6 weeks after surgery and continued for 1 year. The treatment regimen consisted of 6-week cycles in which, in principle, 80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks. The primary end point was overall survival. RESULTS: We randomly assigned 529 patients to the S-1 group and 530 patients to the surgery-only group between October 2001 and December 2004. The trial was stopped on the recommendation of the independent data and safety monitoring committee, because the first interim analysis, performed 1 year after enrollment was completed, showed that the S-1 group had a higher rate of overall survival than the surgery-only group (P=0.002). Analysis of follow-up data showed that the 3-year overall survival rate was 80.1% in the S-1 group and 70.1% in the surgery-only group. The hazard ratio for death in the S-1 group, as compared with the surgery-only group, was 0.68 (95% confidence interval, 0.52 to 0.87; P=0.003). Adverse events of grade 3 or grade 4 (defined according to the Common Toxicity Criteria of the National Cancer Institute) that were relatively common in the S-1 group were anorexia (6.0%), nausea (3.7%), and diarrhea (3.1%). CONCLUSIONS: S-1 is an effective adjuvant treatment for East Asian patients who have undergone a D2 dissection for locally advanced gastric cancer. (ClinicalTrials.gov number, NCT00152217 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010187 · Cited by 3,475
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Japanese Classification of Gastric Carcinoma – 2nd English Edition –
Japanese Gastric Cancer Association (1998) · Gastric Cancer · doi:10.1007/pl00011681 · Cited by 2,170
Shirasaka, T., Shimamato, Y., Ohshimo, H., Yamaguchi, M., Kato, T., Yonekura, K., & Fukushima, M. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199607000-00010 · Cited by 820
Bayesian approaches to randomized trials
Spiegelhalter, D. J., Freedman, L. S., & Parmar, M. K. B. (1994) · Journal of the Royal Statistical Society. Series A (Statistics in Society) · doi:10.2307/2983527 · Cited by 720
Tables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 718
The randomization and stratification of patients to clinical trials
Zelen, M. (1974) · Journal of Chronic Diseases · doi:10.1016/0021-9681(74)90015-0 · Cited by 613
Gastric cancer treatment guidelines in Japan
Nakajima, T. (2002) · Gastric Cancer · doi:10.1007/s101200200000 · Cited by 569
Self-citationSakata, Y., Ohtsu, A., Horikoshi, N., Sugimachi, K., Mitachi, Y., & Taguchi, T. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00211-1 · Cited by 565
Cited by
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Japanese gastric cancer treatment guidelines 2014 (ver. 4)
Japanese Gastric Cancer Association (2017) · Gastric Cancer · doi:10.1007/s10120-016-0622-4 · Cited by 2,429
Japanese gastric cancer treatment guidelines 2010 (ver. 3)
Japanese Gastric Cancer Association (2011) · Gastric Cancer · doi:10.1007/s10120-011-0042-4 · Cited by 2,168
Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70035-4 · Cited by 1,847
Self-citationSongun, I., Putter, H., Kranenbarg, E. M.-K., Sasako, M., & van de Velde, C. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70070-x · Cited by 1,765
Self-citationJapanese gastric cancer treatment guidelines 2018 (5th edition)
Japanese Gastric Cancer Association (2021) · Gastric Cancer · doi:10.1007/s10120-020-01042-y · Cited by 1,749
Bang, Y.-J., Kim, Y.-W., Yang, H.-K., Chung, H. C., Park, Y.-K., Lee, K. H., Lee, K.-W., Kim, Y. H., Noh, S.-I., Cho, J. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61873-4 · Cited by 1,705
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Smyth, E. C., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw350 · Cited by 1,555
Machlowska, J., Baj, J., Sitarz, M., Maciejewski, R., & Sitarz, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114012 · Cited by 1,520
Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T., Nashimoto, A., Fujii, M., Nakajima, T., & Ohashi, Y. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5908 · Cited by 1,434
Self-citationGastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Okines, A., Verheij, M., Allum, W., Cunningham, D., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq164 · Cited by 1,300
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Uesaka, K., Boku, N., Fukutomi, A., Okamura, Y., Konishi, M., Matsumoto, I., Kaneoka, Y., Shimizu, Y., Nakamori, S., Sakamoto, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30583-9 · Cited by 1,115
Self-citationNoh, S. H., Park, S. R., Yang, H.-K., Chung, H. C., Chung, I.-J., Kim, S.-W., Kim, H.-H., Choi, J.-H., Kim, H.-K., Yu, W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70473-5 · Cited by 1,049
D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer
Sasako, M., Sano, T., Yamamoto, S., Kurokawa, Y., Nashimoto, A., Kurita, A., Hiratsuka, M., Tsujinaka, T., Kinoshita, T., Arai, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707035 · Cited by 1,021
Self-citationHartgrink, H. H., Jansen, E. P., van Grieken, N. C., & van de Velde, C. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60617-6 · Cited by 875
Wang, F., Shen, L., Li, J., Zhou, Z., Liang, H., Zhang, X., Tang, L., Xin, Y., Jin, J., Zhang, Y., et al. (2019) · Cancer Communications · doi:10.1186/s40880-019-0349-9 · Cited by 810
Lee, J., Lim, D. H., Kim, S., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Choi, M. G., Sohn, T. S., Noh, J. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1953 · Cited by 803
Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer: A Meta-analysis
(2010) · JAMA · doi:10.1001/jama.2010.534 · Cited by 794
Guidelines for the management of oesophageal and gastric cancer
Allum, W. H., Blazeby, J. M., Griffin, S. M., Cunningham, D., Jankowski, J. A., Wong, R., & On behalf of the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, T. B. S. O. G. A. T. B. A. O. S. O. (2011) · Gut · doi:10.1136/gut.2010.228254 · Cited by 793
Yu, J., Huang, C., Sun, Y., Su, X., Cao, H., Hu, J., Wang, K., Suo, J., Tao, K., He, X., et al. (2019) · JAMA · doi:10.1001/jama.2019.5359 · Cited by 690
Hu, Y., Huang, C., Sun, Y., Su, X., Cao, H., Hu, J., Xue, Y., Suo, J., Tao, K., He, X., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7215 · Cited by 686
Wang, F., Zhang, X., Li, Y., Tang, L., Qu, X., Ying, J., Zhang, J., Sun, L., Lin, R., Qiu, H., et al. (2021) · Cancer Communications · doi:10.1002/cac2.12193 · Cited by 624
Orditura, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1635 · Cited by 623
Ajani, J. A., Lee, J., Sano, T., Janjigian, Y. Y., Fan, D., & Song, S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.36 · Cited by 594
Ajani, J. A., Rodriguez, W., Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V., Vynnychenko, I., Garin, A., Lang, I., & Falcon, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4706 · Cited by 550
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
Registration Committee of the Japanese Gastric Cancer Association, Katai, H., Ishikawa, T., Akazawa, K., Isobe, Y., Miyashiro, I., Oda, I., Tsujitani, S., Ono, H., Tanabe, S., et al. (2018) · Gastric Cancer · doi:10.1007/s10120-017-0716-7 · Cited by 494
Self-citationSohn, B. H., Hwang, J.-E., Jang, H.-J., Lee, H.-S., Oh, S. C., Shim, J.-J., Lee, K.-W., Kim, E. H., Yim, S. Y., Lee, S. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2211 · Cited by 489
Pietrantonio, F., Miceli, R., Raimondi, A., Kim, Y. W., Kang, W. K., Langley, R. E., Choi, Y. Y., Kim, K.-M., Nankivell, M. G., Morano, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01124 · Cited by 487
Chemotherapy for advanced gastric cancer
Wagner, A. D., Unverzagt, S., Grothe, W., Kleber, G., Grothey, A., Haerting, J., & Fleig, W. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub3 · Cited by 472
ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer
Jiang, Y., Zhang, Q., Hu, Y., Li, T., Yu, J., Zhao, L., Ye, G., Deng, H., Mou, T., Cai, S., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002116 · Cited by 458
Zhang, X., Liang, H., Li, Z., Xue, Y., Wang, Y., Zhou, Z., Yu, J., Bu, Z., Chen, L., Du, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00297-7 · Cited by 437
Wang, F., Zhang, X., Tang, L., Wu, Q., Cai, M., Li, Y., Qu, X., Qiu, H., Zhang, Y., Ying, J., et al. (2024) · Cancer Communications · doi:10.1002/cac2.12516 · Cited by 428
Park, S. H., Sohn, T. S., Lee, J., Lim, D. H., Hong, M. E., Kim, K.-M., Sohn, I., Jung, S. H., Choi, M. G., Lee, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3930 · Cited by 427
Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype
Oh, S. C., Sohn, B. H., Cheong, J.-H., Kim, S.-B., Lee, J. E., Park, K. C., Lee, S. H., Park, J.-L., Park, Y.-Y., Lee, H.-S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04179-8 · Cited by 424
Gastric cancer—molecular and clinical dimensions
Wadhwa, R., Song, S., Lee, J.-S., Yao, Y., Wei, Q., & Ajani, J. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.170 · Cited by 423
Yoshida, K., Kodera, Y., Kochi, M., Ichikawa, W., Kakeji, Y., Sano, T., Nagao, N., Takahashi, M., Takagane, A., Watanabe, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01138 · Cited by 392
Self-citationKorean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach
Guideline Committee of the Korean Gastric Cancer Association (KGCA), D. W. G. &. R. P. (2019) · Journal of Gastric Cancer · doi:10.5230/jgc.2019.19.e8 · Cited by 392
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
Shitara, K., Rha, S. Y., Wyrwicz, L. S., Oshima, T., Karaseva, N., Osipov, M., Yasui, H., Yabusaki, H., Afanasyev, S., Park, Y.-K., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00541-7 · Cited by 384
Catalano, V., Labianca, R., Beretta, G. D., Gatta, G., de Braud, F., & Van Cutsem, E. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.004 · Cited by 365
Kang, Y.-K., Yook, J. H., Park, Y.-K., Lee, J. S., Kim, Y.-W., Kim, J. Y., Ryu, M.-H., Rha, S. Y., Chung, I. J., Kim, I.-H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02914 · Cited by 359
Janjigian, Y. Y., Werner, D., Pauligk, C., Steinmetz, K., Kelsen, D. P., Jäger, E., Altmannsberger, H. M., Robinson, E., Tafe, L. J., Tang, L. H., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds104 · Cited by 356
Tokunaga, M., Tanizawa, Y., Bando, E., Kawamura, T., & Terashima, M. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2720-9 · Cited by 337
Nomogram Predicting Long-Term Survival After D2 Gastrectomy for Gastric Cancer
Han, D.-S., Suh, Y.-S., Kong, S.-H., Lee, H.-J., Choi, Y., Aikou, S., Sano, T., Park, B.-J., Kim, W.-H., & Yang, H.-K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.8343 · Cited by 333
Sano, T., Sasako, M., Mizusawa, J., Yamamoto, S., Katai, H., Yoshikawa, T., Nashimoto, A., Ito, S., Kaji, M., Imamura, H., et al. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000001814 · Cited by 323
Self-citationMetronomics: towards personalized chemotherapy?
André, N., Carré, M., & Pasquier, E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.89 · Cited by 320
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Kim, T.-H., Kim, I.-H., Kang, S. J., Choi, M., Kim, B.-H., Eom, B. W., Kim, B. J., Min, B.-H., Choi, C. I., Shin, C. M., et al. (2023) · Journal of Gastric Cancer · doi:10.5230/jgc.2023.23.e11 · Cited by 288
Nakachi, K., Ikeda, M., Konishi, M., Nomura, S., Katayama, H., Kataoka, T., Todaka, A., Yanagimoto, H., Morinaga, S., Kobayashi, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02038-4 · Cited by 258
Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer
Jiang, Y., Li, T., Liang, X., Hu, Y., Huang, L., Liao, Z., Zhao, L., Han, Z., Zhu, S., Wang, M., et al. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.1087 · Cited by 152
S-1: a promising new oral fluoropyrimidine derivative
Saif, M. W., Syrigos, K. N., & Katirtzoglou, N. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902729412 · Cited by 101
Metadata
- Authors
- Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., Furukawa, H., Nakajima, T., Ohashi, Y., Imamura, H., Higashino, M., Yamamura, Y., Kurita, A., & Arai, K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11
- Volume
- 357
- Issue
- 18
- Pages
- 1810-1820
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2137991416
- Cited by
- 2,517
- References
- 18
- FWCI
- 80.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.